Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options.
Grassi
Guido
G
Clinica Medica, Università Milano-Bicocca, Via Donizetti 106, 20052 Monza (Mi), Italy. guido.grassi@unimib.it
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004039:Diet, Sodium-Restricted; D004232:Diuretics / Q000627:therapeutic use; D005081:Exercise Therapy; D006801:Humans; D006973:Hypertension / Q000503:physiopathology* / Q000628:therapy; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D014665:Vasodilator Agents / Q000627:therapeutic use; D015431:Weight Loss
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D014665:Vasodilator Agents